文献速递浆细胞疾病

Iberdomide联合低剂量环磷酰胺和地塞米松治疗复发难治多发性骨髓瘤的II期ICON研究

Iberdomide plus low-dose cyclophosphamide and dexamethasone in patients with relapsed and refractory multiple myeloma (the ICON study): a multicentre, single-arm, phase 2 trial.
PubMed 文献 · Lancet Haematol · 2026-01-01

ICON研究是一项在荷兰8家医院开展的前瞻性、单臂、II期开放标签试验,纳入61例既往接受2-4线治疗且来那度胺难治的复发难治多发性骨髓瘤患者,评估口服Iberdomide联合低剂量环磷酰胺和地塞米松(IberCd)的疗效与安全性。IberCd全口服方案显示出具有临床意义的活性,为既往接受2-4线治疗的患者提供了有价值的治疗选择。

要点

  • 最常见3-4级不良事件为中性粒细胞减少(56%)和感染(34%)。
  • 治疗相关严重不良事件发生率为41%,治疗相关死亡1例(2%)。

核心结论

  • IberCd是复发难治多发性骨髓瘤的全口服且具有活性的联合方案,显示出具有临床意义的活性。
  • 该方案为既往接受2-4线治疗的患者提供了有价值的治疗选择,与其他可用治疗相比具有优势。

研究设计与样本

  • ICON研究为前瞻性、单臂、II期、开放标签研究,在荷兰8家医院开展。
  • 纳入年龄≥18岁、来那度胺难治的复发难治多发性骨髓瘤患者,既往接受2-4线治疗,WHO体能状态0-2。
  • 共61例患者接受IberCd治疗并纳入分析(29例女性[48%],32例男性[52%])。
  • 主要终点为无进展生存期,定义为从治疗开始至疾病进展或死亡的时间。

主要发现

  • 中位既往治疗线数为3(范围2-5);52例(85%)患者三药暴露,27例(44%)患者三药难治。
  • 最常见3-4级不良事件为中性粒细胞减少(34例[56%])和感染(21例[34%])。
  • 治疗相关严重不良事件发生于25例(41%)患者,感染为最常见(48例严重不良事件中34例[71%])。
  • 治疗相关死亡1例(2%),原因为COVID-19。

临床怎么用

  • 对于既往接受2-4线治疗且来那度胺难治的复发难治多发性骨髓瘤患者,可考虑IberCd全口服联合方案。
  • 治疗期间需每日血栓预防:口服阿司匹林80 mg或口服氨基水杨酸钙100 mg;有静脉血栓栓塞史者仅接受低分子肝素皮下注射。

局限性

  • 研究为单臂设计,未设对照组。
  • 样本量较小(61例),随访时间有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Iberdomide is an oral cereblon E3 ligase modulator with higher affinity to cereblon than immunomodulatory drugs, leading to improved direct anti-myeloma activity and enhanced immunostimulatory effects. We aimed to evaluate the safety and activity of iberdomide plus low-dose cyclophosphamide and dexamethasone (IberCd) in patients with relapsed and refractory multiple myeloma. METHODS: The ICON study is a prospective, single-arm, phase 2, open-label study conducted in eight hospitals in the Netherlands. We enrolled patients (aged ≥18 years) with relapsed and refractory multiple myeloma (lenalidomide-refractory) who had received two to four previous lines of therapy and had a WHO performance status of 0-2. Patients were treated with oral iberdomide (1·6 mg/day on days 1-21 of each 28-day cycle), oral low-dose cyclophosphamide (50 mg/day on days 1-28), and oral dexamethasone (40 mg [20 mg in patients age >75 years] once a week) until progression. All patients received thrombosis prophylaxis daily: 80 mg oral aspirin or 100 mg oral carbasalate calcium. Patients with a previous history of venous thromboembolism received only low molecular-weight heparin by subcutaneous injection. The primary endpoint was progression-free survival, defined as time from the start of treatment to the date of progression or death. Activity and safety were assessed in all patients who started treatment. This trial was registered at ClinicalTrials.gov (NCT04392037) and is ongoing. FINDINGS: Between Feb 17, 2021, and July 7, 2023, 61 patients were enrolled and received IberCd treatment (29 [48%] were female and 32 [52%] patients were male). The median number of previous lines of therapy was 3 (range 2-5); 52 (85%) patients were triple-class exposed and 27 (44%) had triple-class refractory disease. 50 patients discontinued study treatment, 39 of whom due to progressive disease, but all 61 patients were included in the main analysis population. After a median follow-up of 25·4 months (IQR 19·7-31·6), the median progression-free survival was 17·6 months (one-sided 95% CI 16·6-19·9). In all 61 patients, the most common grade 3-4 adverse events were neutropenia (34 [56%] patients) and infections (21 [34%] patients). Treatment-related serious adverse events were reported in 25 (41%) patients, with infections being the most common (34 [71%] of 48 serious adverse events). Treatment-related death occurred in one (2%) patient due to COVID-19. INTERPRETATION: IberCd is an all-oral and active combination for patients with relapsed and refractory multiple myeloma that showed clinically meaningful activity. This regimen offers a valuable treatment option for patients who have received two to four previous lines of therapy and compares favourably with other available treatments. FUNDING: Bristol Myers Squibb.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Korst CLBM, Plattel W, de Kort EA, et al. Iberdomide plus low-dose cyclophosphamide and dexamethasone in patients with relapsed and refractory multiple myeloma (the ICON study): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2026. PMID: 41482445. doi:10.1016/S2352-3026(25)00298-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。